Omada is trading publicly after 14 years of providing support to patients with weight-related chronic illnesses. Leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such ...

The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy ...

Semaglutide effects the salivary glands in the mouth. It does this by reducing saliva production ( hyposalivation ), which ...

Dementia experts have said that “hope is on the horizon” after a new review shows a rise in the number of potential drugs that could treat or prevent Alzheimer’s disease. Some 138 treatments are being ...

According to leaders in obesity and nutrition research, following these key nutrition guidelines will make the most of GLP-1 ...

It was just from eating in a calorie deficit but I tried to educate myself on the scientific way of losing weight healthily'. Then, in January 2024, Ms Crabtree committed herself to preparing for a ...

(Gilbert, 6/11) CBS News: Ozempic Side Effects Could Lead To Hospitalization—And Doctors Warn That Long-Term Impacts Remain Unknown Dr. Meera Shah, an endocrinologist at the Mayo Clinic, said that by ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

Nausea is one of the biggest side effects of medications like Ozempic and Wegovy, and that can always lead to vomiting, Godwin says. In June, the American Society of Anesthesiologists recommended ...

Actress Mindy Kaling made a dazzling appearance on Wednesday (May 21) at longtime collaborator Michael Schur’s Hollywood Walk of Fame ceremony, once again turning heads with her dramatically ...

Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when ...

Megan Greenwell was the editor in chief of Deadspin when it was acquired in 2019 by a Boston-based private equity firm. After three months of watching her new bosses make what seemed to her to be ...